Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study is a randomized ,single center clinical study which is designed to investigate
whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent
survival in resectable mucosal melanoma.
All the eligible patients were assigned to receive Lenvatinib once a day (QD) for 6 weeks
plus pembrolizumab on Day 1 of each 21-day cycle (Q3W) concurrently on days 1 and 22,
followed by surgery and 18 cycles of Pembrolizumab 200mg q3w of adjuvant phase.